选择性共价抑制剂FGFR4的设计,合成和生物评估
Xiaojuan Chen1, Huiliang Li2, Qianmeng Lin1
1Department of Oncology, NHC Key Laboratory of Cancer Proteomics, State Local Joint Engineering Laboratory for Anticancer Drugs, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
一种新型的共价抑制剂CXF-007有效向纤维细胞生长因子受体4 (FGFR4) 和它的突变. 这一发现为开发针对异常FGF19/FGFR4信号驱动的固体瘤的抗癌疗法提供了有希望的新策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 异常的纤维细胞生长因子19 (FGF19) /纤维细胞生长因子受体4 (FGFR4) 信号驱动各种固体瘤的瘤发生.
- 对于抗癌药物开发来说,FGFR4是重要的治疗标.
研究的目的:
- 设计和合成针对FGFR4.4的新型共价抑制剂.
- 评估这些化合物对FGFR4及其突变的抑制活性和抗瘤潜力.
主要方法:
- 合成双烯胺共价FGFR4抑制剂.
- 在体外评估对FGFRs和FGFR4突变的抑制活性.
- 质谱和晶体结构分析以确认共价结合.
- 对肝细胞癌和乳腺癌细胞系中的抗瘤活性的评估.
主要成果:
- CXF-007证明了FGFR4及其氨酸突变的强大和选择性抑制.
- 证实了CXF-007与FGFR4的Cys552和FGFR1的Cys488的共价结合.
- 通过持续抑制FGFR4通路,CXF-007在相关癌细胞系中表现出显著的抗瘤作用.
结论:
- CXF-007是一种新的共价FGFR4抑制剂,具有克服药物诱导突变的潜力.
- 这种化合物为由异常FGF19/FGFR4信号驱动的癌症提供了一个有希望的新疗法策略.
更多相关视频
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
07:32Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019
相关概念视频
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Drug Discovery: Overview
Drug-Receptor Bonds
In...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
